Phase 2 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose solid tumour has been confirmed by laboratory testing of tissue or cells, and is either locally advanced (unable to be surgically removed) or has spread to other parts of the body, and for whom no standard treatment is available, suitable, or tolerable.
- People aged 18 or older who are male, or female and neither pregnant nor breastfeeding.
- People with a general health and activity level rated as 0 or 1 on the ECOG scale, meaning largely able to carry out normal daily activities (confirm with trial site).
- People who have at least one tumour that can be measured using standard imaging guidelines.
- People whose doctor estimates they have a life expectancy of more than 3 months.
- People who are able to swallow oral medications and are willing to keep a daily record of taking the study drug.
- People with adequate blood counts, kidney function, and liver function as determined by testing.
- People who are able to understand and willing to sign a written consent form.
Who may not be able to join:
- People with a history of another type of cancer.
- People who have brain metastases causing symptoms that require more than 10 mg per day of prednisolone (a steroid medication).
- People with significant heart or blood vessel disease.
- People with a currently active hepatitis B, hepatitis C, or HIV/AIDS-related illness.
- People who have received a live vaccine within the past 30 days.
- People with a history of active autoimmune conditions, or who are currently taking medication that suppresses the immune system.
- People who still have side effects from previous radiation or chemotherapy that have not improved to a mild level (Grade 2 or lower).
- People currently receiving other cancer treatments, other investigational drugs, or certain medications that strongly interact with a liver enzyme called CYP3A (confirm specific medications with trial site).
- People who have previously been treated with a type of drug called an HPK1 inhibitor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hui ouyang, Dr., VP
Phone: 8617728075858
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose-limiting toxicity (DLT) events during the DLT monitoring period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.